| |
C-Peptide, dog  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP11115-0.5 mg
| 0.5 mg | $ 109.25 | HPLC: 20050919140132 (PDF)
MASS SPECE: 20050919140154 (PDF)
MSDS: 20080814053920 (PDF)
References:
- Montgomery TM, et al. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. J. Vet. Intern. Med. May 1996; 10(3): 116-122.
- Morishima T, et al. The measurement and validation of the nonsteady-state rates of C-peptide appearance in the dog. Diabetologia. Jul 1986; 29(7): 440-446.
- Polonsky KS, et al. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J. Clin. Invest. Nov 1984; 74(5): 1821-1829.
|
|---|
| Full Name | |
Sequence
(one-letter code) |
EVEDLQVRDVELAGAPGEGGLQPLALEGALQ | Sequence
(three-letter code) | {GLU}{VAL}{GLU}{ASP}{LEU}{GLN}{VAL}{ARG}{ASP}{VAL}
{GLU}{LEU}{ALA}{GLY}{ALA}{PRO}{GLY}{GLU}{GLY}{GLY}
{LEU}{GLN}{PRO}{LEU}{ALA}{LEU}{GLU}{GLY}{ALA}{LEU}
{GLN} |
|---|
| Description | The C-peptide of proinsulin is important for the biosynthesis of insulin but has for a long time been considered to be biologically inert. Data now indicates that C-peptide administration is accompanied by augmented blood flow in skeletal muscle and skin, diminished glomerular hyperfiltration, reduced urinary albumin excretion, and improved nerve function. The possibility exists that C-peptide replacement, together with insulin administration, may prevent the development or retard the progression of long-term complications in type 1 diabetes. |
|---|
| Formula | C137H225N37O49 |
|---|
| M.W. | 3174.49 |
|---|
| Purity | > 95% |
|---|
| Storage | Store at -20°C. |
| * For Non-Clinical Research Use Only *
Our customer service is available 24 hours a day, Monday through Friday. You may contact us any time for assistance.
|
|
